Ongoing

2

320

Europe

Pardoprunox, SLV308, Film-coated tablet, Tablet, Mirapex

Solvay Pharmaceuticals B.V.

Early Stage Parkinson’s Disease

 

 

Ongoing

2

202

Europe

amantadine, Capsule, mantadix

CHU de Toulouse, Programme Hospitalier de Recherche Clinique, Enveloppe Nationale 2011

Maladie de Parkinson, Maladie de Parkinson, Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

2

40

Europe

[18F]-Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile (FDDNP, FDDNP, Injection

Fundació Clínic per a la Recerca Biomédica, Ministerio de Ciencia e Innovación

Atypical Parkinsonism Parkinsonismos Atipicos, Not typical form of parkinsonism Formas atipicas de parkinsonismo, Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

2

240

Europe

OSU6162 similar to (-)-OSU 6162, Coated tablet

A. Carlsson Research AB, A. Carlsson Research AB

Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy Parkinsons sjukdom Huntingtons sjukdom Multipel scleros Traumatisk hjärnskada Stroke Myalgisk encefalomyelit Narkolepsi, Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy Parkinsons sjukdom Huntingtons sjukdom Multipel scleros Traumatisk hjärnskada Stroke Myalgisk encefalomyelit Narkolepsi, Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

2

45

Europe

Mestinon, RVG 03820, Tablet, pyridostigmine bromide

Universtiy Medical Center Utrecht, Prinses Beatrix Fonds

Proximal spinal muscular atrophy (SMA) is characterized by weakness of predominantly axial and proximal muscle groups and is caused by homozygous deletion of the survival motor neuron 1 (SMN1)-gene. There are 4 SMA types (type 1-4), with a descending order of severity. Age at onset and achieved motor milestones are the characteristics to define severity. Treatment of SMA is exclusively supportive. Spinale spieratrofie (SMA) is een aandoening gekenmerkt door proximale spierzwakte door degeneratie van motorneuronen in de voorhoorncellen van het ruggenmerg. SMA wordt veroorzaakt door een homzygote deletie van het SMN1-gen. Er zijn 4 types SMA, geclassificeerd op basis van behaalde motorische mijlpalen en leeftijd van eerste symtpomen. De behandeling van SMA is ondersteunend., Spinal muscular atrophy (SMA) is a disorder characterized by muscle weakness caused by loss of motor cells of the spinal cord. SMA is a genentic disease. Treatment of SMA is supportive. Spinale spieratrofie (SMA) is een aandoening met proximale spierzwakte door verlies van motorische cellen in het ruggenmerg. SMA is een genetische aandoening. De behandeling van SMA is ondersteunend., Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

2

20

Europe

Ebixa, Ebixa, Ebixa

Neuropsychiatric clinic

Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder.

 

 

Ongoing

2

24

Europe

Apomorphine hydrochloride, VR040,

Vectura Group plc

Hypomobility (off or freezing) episodes associated with advanced Parkinson\'s disease

 

 

Ongoing

2

40

Europe

Nicorette 5 mg/ 16 h, Nicorette 10mg/ 16 h, Nicorette 15 mg/ 16 h, Nicorette 5 mg/ 16 h, Nicorette 5 mg/ 16 h

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

Maladie Parkinson

 

 

Ongoing

2

7

Europe

Neorecormon, EU1/97/031-032, Neorecormon, Neorecormon

Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie

Friedreich\'s ataxia (FRDA) is the most common autosomal recessive neurodegenerativ disease (1:50 000) affecting the central and peripheral nervous system. Extraneural organs are also affected during the course of the disease as a significant proportian of patients develop cardiomyopathy or diabetes. FRDA is caused by a GAA triplet expansion in the FRDA gene on chromosome 9q13 resulting in a loss of function of the gene product Frataxin.

 

 

Ongoing

2

24

Europe

not available, OSU 6162 similar to (-)-OSU 6162,

Sahlgrenska University Hospital

Patients with Huntington´s disease

 

 

Ongoing

2

16

Europe

Rilmenidine, Hyperium, Hyperium

Cambridge University Hospitals NHS Foundation Trust and University of Cambridge

Huntington\'s Disease

 

 

Ongoing

2

56

Europe

Tablet, Parapres

INSTITUT DE RECERCA HSCSP, Institut de Recerca HSCSP

Parkinson's Disease Enfermedad de Parkinson, Parkinson's disease Enfermedad de Parkinson, Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

2

48

Europe

Nabilone, Capsule

Medizinische Universität Innsbruck, Universitätsklinik für Neurologie, AOP Orphan Pharmaceuticals AG

Subjects with non-motor symptoms of Parkinson´s disease, Parkinson´s disease, Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

2

46

Europe

Ro 723-4292/F02, Solution for injection

F.Hoffmann La-Roche Ltd, F.Hoffmann La-Roche Ltd - Basel

Early Manifest Huntington's Disease, Early Manifest Huntington's Disease, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

 

 

Ongoing

2

14

Europe

(2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide), [11C]SMW139, Injection

Juha Rinne / PET Centre

Parkinson´s disease, Parkinson´s disease, Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

2

8

Europe

Levodopa powder for inhalation, Levodopa Cyclops, Inhalation powder, Orodispersible tablet, Madopar 125 mg, orodispersible tablet

Pharmaceutical Technology and Biopharmacy, University of Groningen, Parkinson Vereniging, Martini Ziekenhuis Groningen, University of Groningen

Parkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopamine causes disruption of motor circuits in the brain resulting in motor function impairments like tremor, rigidity and bradykinesia. De ziekte van Parkinson is een progressieve neurodegeneratieve ziekte die wordt gekenmerkt door een tekortschietende dopamineproductie als gevolg van het verlies van dopamineproducerende cellen in de substantia nigra. Een tekort aan dopamine leidt tot de verstoring van motorische verbindingen in de hersenen. Dit resulteert in motorische functiestoornissen, zoals tremor, rigiditeit en bewegingstraagheid., Parkinson's disease is a movement disorder, caused by a lack of the neurotransmitter dopamine in the brain. The main symptoms are shaking, stiffness and slowness of movement. Bij de ziekte van Parkinson is er een tekort aan het stofje dopamine in de hersenen, wat zorgt voor verstoringen van de manier van bewegen. De klachten zijn trillen, stijfheid en traag bewegen., Diseases [C] - Nervous System Diseases [C10]

 

 

Ongoing

1/2

30

Europe

Rasagilin, Rasagilin (Azilect®), Rasagilin (Azilect®)

NeuroCode AG

Parkinsonpatienten, die bezüglich ihrer motorischen Tagesaktivität optimal eingestellt sind, leiden trotzdem vermehrt unter Tagesmüdigkeit und Schlafstörungen (Chaudhuri, 2002). Es wird angenommen, dass eine Umstellung der Patienten von Selegilin auf Rasagilin zu einer deutlichen klinischen Verbesserung, insbesondere der Schlafproblematik führen wird.